Biomarin Pharmaceutical Inc (BMRN)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 167,645 | 141,561 | -64,080 | 854,029 | -23,848 |
| Total stockholders’ equity | US$ in thousands | 4,951,550 | 4,603,160 | 4,265,670 | 4,100,930 | 3,122,380 |
| ROE | 3.39% | 3.08% | -1.50% | 20.83% | -0.76% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $167,645K ÷ $4,951,550K
= 3.39%
Biomarin Pharmaceutical Inc's return on equity (ROE) has fluctuated over the past five years. In 2023, the ROE was 3.39%, a slight increase from 3.08% in 2022. The ROE turned negative in 2021 at -1.50%, following a significant drop from 20.83% in 2020, and a negative ROE of -0.76% in 2019.
The negative ROE in 2021 and 2019 indicates that the company generated net losses relative to shareholders' equity in those years, which could be concerning for investors. The improvement in ROE from 2021 to 2023 shows a positive trend, but the current ROE level is still relatively low compared to the industry average.
It is important for Biomarin Pharmaceutical Inc to continue monitoring and improving its ROE to ensure sustainable growth and profitability for its shareholders in the long term. Additional analysis of the company's financial performance, operations, and strategies may provide further insights into the factors influencing its ROE.
Peer comparison
Dec 31, 2023